- Home
- RIBB vs MGNX Comparison
RIBB vs MGNX Comparison
Compare RIBB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIBB
- MGNX
- Stock Information
- Founded
- RIBB 2024
- MGNX 2000
- Country
- RIBB Japan
- MGNX United States
- Employees
- RIBB N/A
- MGNX N/A
- Industry
- RIBB
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RIBB
- MGNX Health Care
- Exchange
- RIBB NYSE
- MGNX Nasdaq
- Market Cap
- RIBB 64.9M
- MGNX 70.3M
- IPO Year
- RIBB 2025
- MGNX 2013
- Fundamental
- Price
- RIBB N/A
- MGNX $1.43
- Analyst Decision
- RIBB
- MGNX Hold
- Analyst Count
- RIBB 0
- MGNX 10
- Target Price
- RIBB N/A
- MGNX $6.83
- AVG Volume (30 Days)
- RIBB 9.8K
- MGNX 599.1K
- Earning Date
- RIBB 01-01-0001
- MGNX 05-20-2025
- Dividend Yield
- RIBB N/A
- MGNX N/A
- EPS Growth
- RIBB N/A
- MGNX N/A
- EPS
- RIBB N/A
- MGNX N/A
- Revenue
- RIBB N/A
- MGNX $149,962,000.00
- Revenue This Year
- RIBB N/A
- MGNX N/A
- Revenue Next Year
- RIBB N/A
- MGNX $80.86
- P/E Ratio
- RIBB N/A
- MGNX N/A
- Revenue Growth
- RIBB N/A
- MGNX 155.26
- 52 Week Low
- RIBB $9.95
- MGNX $0.99
- 52 Week High
- RIBB $10.45
- MGNX $14.91
- Technical
- Relative Strength Index (RSI)
- RIBB N/A
- MGNX 43.37
- Support Level
- RIBB N/A
- MGNX $1.54
- Resistance Level
- RIBB N/A
- MGNX $1.82
- Average True Range (ATR)
- RIBB 0.00
- MGNX 0.15
- MACD
- RIBB 0.00
- MGNX 0.01
- Stochastic Oscillator
- RIBB 0.00
- MGNX 19.79
About RIBB RIBBON ACQUISITION CORP
Ribbon Acquisition Corp is a blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.